Imricor Medical Systems (ASX:IMR) said it expects a "steady string" of US Food and Drug 510(k) product submissions and approvals through the remainder of the year, according to a Monday filing with the Australian bourse.
During the June quarter, the company's cash balance fell to $50.3 million from $53.9 million in the March quarter.
Shares of the company fell past 3% in recent Monday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。